Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sun Young Rha
Reply to: ‘Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer’
We thank Sang-ji Choi for his thoughtful Correspondence (Choi, S. Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-026-01219-x (2026))1 and for providing an opportunity to clarify our interpretation of the evidence regarding surgery for oligometastatic gastro-oesophageal adenocarcinoma.
Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer
|
Abstract Ceralasertib, an ATR inhibitor, is known to exacerbate replication stress induced by the PARP inhibitor (PARPi) olaparib, with the combination having the potential to overcome PARPi resistance in the clinic. This modular Phase 1 study evaluated the combination in advanced solid tumours, including breast cancer.
By Juanita Lopez, Seock-Ah Im, Sophie Postel-Vinay, Mario Campone, Anthony B El-Khoueiry, Wassim Abida, Tobias Arkenau, Keun-Wook Lee, Sun Young Rha, Duncan I. Jodrell, Rebecca Roylance, Itziar Irurzun-Arana, Gemma Jones Verified, Natalia Lukashchuk, Christine Stephens, Conor Norris, Arsene-Bienvenu Loembé, Emma Dean, Matthew G. Krebs
|
Nature
Verified
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial
Abstract Evorpacept blocks the CD47–signal regulatory protein α interaction, enhancing antibody-dependent cellular phagocytosis.
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
|
Correction to: Nature https://doi.org/10.1038/s41586-026-10718-x Published online 1 July 2026 In the version of this article initially published, the name of Jaime Merchán was misspelled (Jamie Merchan) and is now amended in the HTML and PDF versions of the article.
By Toni K. Choueiri, Jaime R. Merchan, Amita Patnaik, Alexandra Drakaki, Brian Rini Verified, Sun Young Rha, Jae Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra Shao, Pedro Barata, Bradley A McGregor, Paul Foster, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah, Rana R. McKay
|
Nature
Verified
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
|
Abstract Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2α (HIF-2α)1. Here we show that monotherapy with casdatifan—an orally bioavailable, potent and selective HIF-2α inhibitor2—produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC.
By Toni K. Choueiri, Amita Patnaik, Alexandra Drakaki, Brian Rini Verified, Sun Young Rha, Jae Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Pedro Barata, Bradley A McGregor, Paul Foster Verified, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah, Rana R. McKay, Jamie Merchan, Yusra Shao
|
Nature
Verified
Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison
Abstract Objective In the RATIONALE-305 trial, first-line tislelizumab + chemotherapy (CAPOX ([capecitabine + oxaliplatin] or 5-fluorouracil [5-FU] + cisplatin) significantly improved overall and progression-free survival (PFS) versus placebo + chemotherapy in unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC).
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Jazz Pharmaceuticals, BeOne Medicines, and Zymeworks. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Published May 27, 2026 N Engl J Med 2026;394:2002-2014 DOI: 10.1056/NEJMoa2517729 For permission requests, please contact NEJM Reprints at reprints@nejm.org Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Jazz Pharmaceuticals, BeOne Medicines, and Zymeworks.
Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines
Abstract Oncolytic vaccinia virus JX-594 (pexastimogene devacirepvec) selectively replicates in tumour cells and stimulates antitumour immunity; however, its therapeutic potential in gastric cancer (GC) has not been systematically evaluated. In this study, we investigated the antitumour activity of JX-594 across a panel of 49 molecularly characterized GC cell lines and a xenograft mouse model and explored molecular features associated with viral sensitivity.
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons
Abstract The landscape of gastro-oesophageal adenocarcinoma (GEA) management has undergone substantial transformation over the past decade owing to shifts in epidemiology, evolving treatment paradigms and the integration of new therapeutic strategies. The global burden of GEA continues to rise, with differing patterns observed in Asia compared with Western countries.
Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology - Scientific Reports
Abstract We developed a CancerMaster-targeted next generation sequencing (NGS) panel covering 524 key genes specifically designed for the multidimensional molecular profiling of solid tumors. We aimed to establish CancerMaster as an asynchronous and parallel one-stop automated analysis pipeline with a reporting system to overcome the delay in existing NGS approaches.
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium 4:05 PM EST 12/02/2025 - Comtex DUBLIN, Dec.
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort
INTRODUCTION Glioblastoma (GBM) is an aggressive malignant central nervous system (CNS) tumor, accounting for approximately 15% of all CNS tumors and 48% of malignant CNS tumors.1 Standard-of-care treatments for newly diagnosed GBM include surgical resection, when feasible, followed by radiotherapy with concurrent adjuvant systemic therapy, such as temozolomide2 with or without tumor-treating fields.2, 3 Disease progression (PD) is usually rapid with radiotherapy plus temozolomide, with...
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial - Nature Communications
Abstract There is a need for novel therapies for patients with previously treated HER2-positive gastroesophageal adenocarcinoma (GEA). This phase 1 (NCT02892123) dose-escalation and expansion trial evaluated zanidatamab (a dual HER2-targeted bispecific antibody) ± chemotherapy in previously treated patients with HER2-expressing, locally advanced/metastatic cancers. Here, we report the outcomes for GEA cohorts receiving zanidatamab monotherapy or with chemotherapy (paclitaxel or capecitabine).
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
Keywords futibatinib TAS-120 fibroblast growth factor receptor fibroblast growth factor receptor 2 FGFR2 gastric cancer gastroesophageal junction stomach cancer Get full text access Log in, subscribe or purchase for full access. References 1. Thrift, A.P. ∙ Wenker, T.N. ∙ El-Serag, H.B. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention Nat Rev Clin Oncol. 2023; 20:338-349 2. Rawla, P. ∙ Sunkara, T. ∙ Barsouk, A.
Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | Journal of Clinical Oncology
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
Get full text access Log in, subscribe or purchase for full access. References 1. Sung, H ∙ Ferlay, J ∙ Siegel, RL ∙ et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2021; 71:209-249 2. Abnet, CC ∙ Arnold, M ∙ Wei, WQ Epidemiology of esophageal squamous cell carcinoma Gastroenterology. 2018; 154:360-373 3. Arnold, M ∙ Ferlay, J ∙ van Berge Henegouwen, MI ∙ et al.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
Abstract In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
Abstract In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis.
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial - Nature Communications
Abstract We aimed to determine the activity of the anti-VEGF receptor tyrosine-kinase inhibitor, pazopanib, combined with the anti-PD-L1 inhibitor, durvalumab, in metastatic and/or recurrent soft tissue sarcoma (STS). In this single-arm phase 2 trial (NCT03798106), treatment consisted of pazopanib 800 mg orally once a day and durvalumab 1500 mg once every 3 weeks.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study - The Lancet Oncology
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Background The benefit of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma is unknown. We assess the antitumor activity of neoadjuvant and adjuvant pembrolizumab plus chemotherapy in patients with locally advanced resectable gastric or gastro-oesophageal adenocarcinoma.
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | Journal of Clinical Oncology
CONTEXT Key Objective To screen multiple targeted agents as second-line treatment for patients with human epidermal growth factor 2 (HER2)–negative advanced gastric cancer (AGC) in a standard-of-care controlled umbrella trial design.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial - The Lancet Oncology
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Background Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-related quality-of-life (HRQOL) outcomes from the CLEAR study. Methods This open-label, randomised, phase 3 study was done across 200 hospitals and cancer centres in 20 countries.
Fear of cancer recurrence and its predictors and outcomes among cancer survivors: A descriptive correlational study
Highlights • Fear of cancer recurrence was explained as a process. • Fear of cancer severity function as a moderator between both psychological distress and functioning impairments. • Predictors for high fear of cancer recurrence severity were identified as being female and having a breast cancer diagnosis. Abstract Purpose Fear of cancer recurrence (FCR) is a major issue in the context of survivorship. The identification of predictors and outcomes of FCR is a top research priority.
Self-efficacy for coping with cancer and quality of life in advanced gastric cancer patients
Highlights • Self-efficacy for seeking and understanding medical information was the highest. • Ranked subscale, while using spiritual coping was the lowest ranked subscale.
Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sun Young
Contact Sun Young, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack